GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cochlear Ltd (ASX:COH) » Definitions » Price-to-Free-Cash-Flow

Cochlear (ASX:COH) Price-to-Free-Cash-Flow : 70.29 (As of May. 24, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Cochlear Price-to-Free-Cash-Flow?

As of today (2025-05-24), Cochlear's share price is A$268.36. Cochlear's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was A$3.82. Hence, Cochlear's Price-to-Free-Cash-Flow Ratio for today is 70.29.

The historical rank and industry rank for Cochlear's Price-to-Free-Cash-Flow or its related term are showing as below:

ASX:COH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 28.4   Med: 56.39   Max: 85
Current: 70.28

During the past 13 years, Cochlear's highest Price-to-Free-Cash-Flow Ratio was 85.00. The lowest was 28.40. And the median was 56.39.

ASX:COH's Price-to-Free-Cash-Flow is ranked worse than
79.3% of 372 companies
in the Medical Devices & Instruments industry
Industry Median: 28.445 vs ASX:COH: 70.28

Cochlear's Free Cash Flow per Share for the six months ended in Dec. 2024 was A$1.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was A$3.82.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Cochlear was -19.90% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 14.60% per year.

During the past 13 years, Cochlear's highest 3-Year average Free Cash Flow per Share Growth Rate was 131.50% per year. The lowest was -39.70% per year. And the median was 9.85% per year.


Cochlear Price-to-Free-Cash-Flow Historical Data

The historical data trend for Cochlear's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cochlear Price-to-Free-Cash-Flow Chart

Cochlear Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 83.25 43.66 56.64 73.00

Cochlear Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 56.64 - 73.00 -

Competitive Comparison of Cochlear's Price-to-Free-Cash-Flow

For the Medical Devices subindustry, Cochlear's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cochlear's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cochlear's Price-to-Free-Cash-Flow falls into.


;
;

Cochlear Price-to-Free-Cash-Flow Calculation

Cochlear's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=268.36/3.818
=70.29

Cochlear's Share Price of today is A$268.36.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cochlear's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was A$3.82.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Cochlear  (ASX:COH) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Cochlear Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cochlear's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cochlear Business Description

Traded in Other Exchanges
Address
1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.

Cochlear Headlines

No Headlines